Researchers report in Cell Death Discovery that inhibiting PHGDH can overcome resistance to dabrafenib in BRAF V600E anaplastic thyroid carcinoma by inducing metabolic rewiring. The work by S.Y. Kim and M.H. You identifies PHGDH as a potential vulnerability in resistant tumor cells, positioning metabolic targeting as a route to extend response to MAPK-pathway inhibition.